Literature DB >> 16998493

Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45.

Sandra J van Vliet1, Sonja I Gringhuis, Teunis B H Geijtenbeek, Yvette van Kooyk.   

Abstract

Homeostatic control of T cells involves tight regulation of effector T cells to prevent excessive activation that can cause tissue damage and autoimmunity. Little is known, however, about whether antigen-presenting cells (APCs) are also involved in maintaining immune system homeostasis once effector T cells are stimulated. Here we found that immature APCs downregulated effector T cell function by a mechanism involving the C-type lectin MGL expressed by APCs. Glycosylation-dependent interactions of MGL with CD45 on effector T cells negatively regulated T cell receptor-mediated signaling and T cell-dependent cytokine responses, which in turn decreased T cell proliferation and increased T cell death. Thus, regulation of effector T cells by MGL expressed on APCs may provide a target for regulating chronic inflammatory and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998493     DOI: 10.1038/ni1390

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  68 in total

1.  A sweet path toward tolerance in the gut.

Authors:  Gabriel A Rabinovich
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

Review 2.  T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.

Authors:  Mary C Clark; Linda G Baum
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

3.  Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.

Authors:  Filipa Marcelo; Nitin Supekar; Francisco Corzana; Joost C van der Horst; Ilona M Vuist; David Live; Geert-Jan P H Boons; David F Smith; Sandra J van Vliet
Journal:  J Biol Chem       Date:  2018-11-30       Impact factor: 5.157

Review 4.  Inflammatory bowel disease, past, present and future: lessons from animal models.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

5.  Macrophage Galactose-Type Lectin-1 Deficiency Is Associated with Increased Neutrophilia and Hyperinflammation in Gram-Negative Pneumonia.

Authors:  Christopher N Jondle; Atul Sharma; Tanner J Simonson; Benjamin Larson; Bibhuti B Mishra; Jyotika Sharma
Journal:  J Immunol       Date:  2016-02-24       Impact factor: 5.422

Review 6.  Roles of galectins in inflammatory bowel disease.

Authors:  Akira Hokama; Emiko Mizoguchi; Atsushi Mizoguchi
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

7.  The lectin Jacalin induces human B-lymphocyte apoptosis through glycosylation-dependent interaction with CD45.

Authors:  Bruce Yong Ma; Kaori Yoshida; Makoto Baba; Motohiro Nonaka; Shogo Matsumoto; Nobuko Kawasaki; Shinji Asano; Toshisuke Kawasaki
Journal:  Immunology       Date:  2008-10-30       Impact factor: 7.397

Review 8.  The tumour glyco-code as a novel immune checkpoint for immunotherapy.

Authors:  Ernesto RodrÍguez; Sjoerd T T Schetters; Yvette van Kooyk
Journal:  Nat Rev Immunol       Date:  2018-02-05       Impact factor: 53.106

Review 9.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.